New weekly shot could help shed pounds in obesity trial
NCT ID NCT07279194
First seen Jun 24, 2026 · Last updated Jun 24, 2026
Summary
This study tests a once-weekly injection called HDM1005 for weight loss in 825 Chinese adults who are obese or overweight with related health issues. Participants receive either the drug or a placebo for 52 weeks, plus diet and exercise advice. The main goal is to see how much weight they lose and if at least 5% of body weight is lost after 40 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY & OVERWEIGHT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhongshan Hoapital
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HDM1005 (a weekly injection for weight loss)
What this could lead to
If successful, this could provide a new weekly injection option for significant weight loss in people with obesity or overweight.
What could go wrong
This is a Phase 3 trial, but results may not apply to non-Chinese populations. Side effects from the drug or placebo are possible, and weight regain after stopping is a risk.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.